The FGFR1, FGFR2, FGFR3 inhibitor pemigatinib represents the FGFR-directed agent at the most advanced stage of development, since this molecule has represented the first targeted agent to be approved in CCA so far (Table 1) [75]. Here, FGFR2 is linked to cholangiocarcinoma.